A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu,
Jessica K. Altman,
Geoffrey L. Uy,
Martin S. Tallman,
Ivana Gojo,
Gerard Lozanski,
Ute Burkard,
Annika Osswald,
Pamela James,
Björn Rüter,
William Blum
Affiliations
Sumithira Vasu
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Jessica K. Altman
Division of Hematology/Oncology, Northwestern University, Chicago, Illinois
Geoffrey L. Uy
Washington University School of Medicine, Siteman Cancer Center, St Louis, MO
Martin S. Tallman
Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
Ivana Gojo
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Gerard Lozanski
Department of Pathology, The Ohio State University, Columbus, OH
Ute Burkard
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß
Annika Osswald
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß
